• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Heartbeam Inc.

    7/13/23 4:16:11 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email
    S-8 1 ea181651-s8_heartbeaminc.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on July 13, 2023 

    Registration No. 333-             

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    HEARTBEAM, INC.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   47-4881450
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)

     

    2118 Walsh Avenue, Suite 210

    Santa Clara, CA 95050

    (Address of principal executive offices including zip code)

     

     

     

    2022 EQUITY INCENTIVE PLAN 

    (Full title of the plans)

     

     

     

    Branislav Vajdic

    Chief Executive Officer

    HeartBeam, Inc.

    2118 Walsh Avenue, Suite 210

    Santa Clara, CA 95050

    Telephone: 408-899-4443

    (Name, address, and telephone number, including area code, of agent for service)

     

     

     

    Copy to:

    Scott K. Murano

    Brian C. Appel

    Wilson Sonsini Goodrich & Rosati, P.C.

    Page Mill Road, Palo Alto, CA 94304

    (650) 493-9300

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer ☐ Accelerated filer ☐
      Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☒ 

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTION E

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed to register an additional 7,750,487 shares of common stock of HeartBeam, Inc. (the “Registrant”) reserved for issuance pursuant to future awards under the Registrant’s 2022 Equity Incentive Plan, as amended (the “2022 Plan”).

     

    These additional shares of common stock are securities of the same class as other securities for which previous Registration Statement on Form S-8 were filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on July 13, 2022 (File No. 333-266114) (the “Previous Registration Statement”). In accordance with General Instruction E of Form S-8, the contents of the Previous Registration Statement, including periodic reports filed after the Previous Registration Statement to maintain current information about the Registrant, are incorporated by reference into this Registration Statement.

     

     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    Registrant hereby incorporates by reference into this Registration Statement the following documents and information heretofore filed with the Commission:

     

    (1)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, (File No. 001-41060) filed with the Commission on March 16, 2023 pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

     

    (2)The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-41060) filed with the Commission on November 10, 2021 pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description; and

     

    (3)All reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the filing of the Registrant’s Annual Report referred to in (1) above (other than the portions of such documents not deemed to be filed).

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    II-1

     

      

    Item 8. Exhibits.

     

    Exhibit Number  Description
        
    4.1(1) Specimen Common Stock certificate.
    4.2(2) 2022 Equity Incentive Plan, as amended, and forms of agreement thereunder.
    5.1  Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation
    23.1  Consent of Marcum LLP Independent Registered Public Accounting Firm
    23.2  Consent of Friedman LLP Independent Registered Public Accounting Firm
    23.3  Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (see Exhibit 5.1)
    24.1  Power of Attorney (included on the signature page hereto).
    107.1  Filing Fee Table

     

    (1)Incorporated by reference to Exhibit 4.1 filed with the Registrant’s Registration Statement on Form S-8 (Registration No. 333-261430), filed with the Commission on December 1, 2021.
    (2)Incorporated by reference to Exhibit 10.1 filed with the Registrant’s Registration Statement on Form S-8 (Registration No. 333-266114), filed with the Commission on July 13, 2022.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Santa Clara, State of California on July 13, 2023.

     

      HEARTBEAM, INC.
       
      By: /s/ Branislav Vajdic
        Branislav Vajdic
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Branislav Vajdic and Richard Brounstein, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him or her in his or her name, place and stead, in any and all capacities to sign any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated.

     

    Signature

     

    Title

     

    Date

             
    /s/ Branislav Vajdic   Chief Executive Officer and Director   July 13, 2023
    Branislav Vajdic   (Principal Executive Officer)    
             
    /s/ Richard Brounstein   Chief Financial Officer   July 13, 2023
    Richard Brounstein   (Principal Financial and Accounting Officer)    
             
    /s/ Richard Ferrari  

    Executive Chairman

      July 13, 2023
    Richard Ferrari        
             
    /s/ Willem Elfrink   Director   July 13, 2023
    Willem Elfrink        
             
    /s/ Marga Ortigas-Wedekind   Director   July 13, 2023
    Marga Ortigas-Wedekind        
             
    /s/ George de Urioste   Director   July 13, 2023
    George de Urioste        
             
    /s/ Mark Strome   Director   July 13, 2023
    Mark Strome        
             
    /s/ Kenneth Nelson   Director   July 13, 2023
    Kenneth Nelson        

     

    II-3

     

    Get the next $BEAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAT

    DatePrice TargetRatingAnalyst
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    12/8/2025$2.50Buy
    H.C. Wainwright
    10/31/2025$4.00Buy
    Roth Capital
    12/20/2021$9.00Speculative Buy
    Benchmark
    More analyst ratings

    $BEAT
    SEC Filings

    View All

    SEC Form S-3 filed by Heartbeam Inc.

    S-3 - HeartBeam, Inc. (0001779372) (Filer)

    2/9/26 4:05:55 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Heartbeam Inc. filed SEC Form 8-K: Other Events

    8-K - HeartBeam, Inc. (0001779372) (Filer)

    11/21/25 9:47:46 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Heartbeam Inc.

    10-Q - HeartBeam, Inc. (0001779372) (Filer)

    11/13/25 4:04:16 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Strome Mark E sold $895,000 worth of shares (250,000 units at $3.58) (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    12/22/25 5:44:34 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Director De Urioste George sold $182,090 worth of shares (57,146 units at $3.19), closing all direct ownership in the company (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    12/19/25 5:10:19 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by CFO Cruickshank Tim

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    10/3/25 4:36:53 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference

    HeartBeam Recently Received US Food and Drug Administration (FDA) Clearance for First-Ever Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment Pivotal Milestone Unlocks Multiple Key Initiatives in Company's Growth Strategy HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place January 12-15, 2026 at the Westin St. Francis Hotel in San Francisco, CA. HeartBeam Chief Executive Officer, Robert Eno, and Chief Financial Officer, Timothy Cruickshank, will be available January 12-14 for off-site

    1/5/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment

    FDA Clearance Granted After Successful Appeal, Overturning Prior Not Substantially Equivalent (NSE) Outcome HeartBeam's Credit-Card Sized Device Delivers Clinical-Grade Insights Directly to Patients Anytime, Anywhere Pivotal Milestone Unlocks Multiple Key Initiatives in Company's Growth Strategy HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company's groundbreaking 12-lead electrocardiogram (ECG) synthesis software for the assessment of arrhythmias. This clearance follows HeartBeam's succe

    12/10/25 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HeartBeam upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded HeartBeam from Speculative Buy to Buy and set a new price target of $8.00

    12/11/25 8:45:10 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on HeartBeam with a new price target

    H.C. Wainwright initiated coverage of HeartBeam with a rating of Buy and set a new price target of $2.50

    12/8/25 8:34:44 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Roth Capital initiated coverage on HeartBeam with a new price target

    Roth Capital initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00

    10/31/25 8:19:51 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 8:00:22 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 7:55:14 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

    Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

    5/5/25 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

    First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

    12/16/24 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Financials

    Live finance-specific insights

    View All

    HeartBeam Reports Third Quarter 2025 Results

    Commercial Readiness Plans Accelerating in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software for Arrhythmia Assessment Anticipated FDA Clearance in Q4 2025 is a Major Inflection Point as HeartBeam Evolves into a Commercial-Stage Company Focused on Growth Announced Partnership with HeartNexus to Provide On-Demand Cardiologist Reviews of Synthesized 12-Lead ECGs for Arrhythmia Assessment and Triage Patients Data Presented at AHA Scientific Sessions and HRX Live 2025 Continue to Advance HeartBeam's Pipeline for Ischemia Detection and Deep Learning Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. E

    11/13/25 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, November 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed dur

    10/30/25 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Reports Second Quarter 2025 Results

    Executing on Commercial Readiness Plans in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Engaged in Ongoing Productive Discussions with FDA Related to the 510(k) Application Increased Business Development Resources to Match Inbound Interest from Industry Partners Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter & Subsequent 2025 Operational Highligh

    8/13/25 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    10/25/23 4:01:55 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    8/28/23 4:26:34 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    6/2/23 2:36:13 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care